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Abstract: The 14-3-3 proteins are a family of dimeric eukaryotic proteins that mediate both phosphorylation-dependent 
and -independent protein-protein interactions. Through these interactions, 14-3-3 proteins participate in the regulation of a 
wide range of cellular processes, including cell proliferation, cell cycle progression, and apoptosis. Because of their fun-
damental importance, 14-3-3 proteins have also been implicated in a variety of diseases, including cancer and neurode-
generative disorders. In order to monitor 14-3-3/client protein interactions for the discovery of small molecule 14-3-3 
modulators, we have designed and optimized 14-3-3 protein binding assays based on the amplified luminescent proximity 
homogeneous assay (AlphaScreen) technology. Using the interaction of 14-3-3 with a phosphorylated Raf-1 peptide and a 
nonphosphorylated R18 peptide as model systems, we have established homogenous “add-and-measure” high-throughput 
screening assays. Both assays achieved robust performance with S/B ratios above 7 and Z’ factors above 0.7. Application 
of the known antagonistic peptides in our studies further validated the assay for screening of chemical compound libraries 
to identify small molecules that can modulate 14-3-3 protein-protein interactions.  
Keywords: 14-3-3, AlphaScreen, protein-protein interaction, HTS. 
INTRODUCTION  
  The 14-3-3 proteins are a family of eukaryotic regulatory 
proteins that can recognize phosphoserine/threonine 
(pSer/Thr)-containing motifs utilized by a variety of signal 
transduction pathways [1-5]. 14-3-3 can directly bind pSer or 
pThr in specific sequence contexts (Fig. 1) [6, 7]. Sequences 
around pS259 and pS621 in Raf-1 are well studied examples. 
This phosphorylation-dictated interaction allows 14-3-3 pro-
teins to bind a multitude of functionally diverse molecules, 
including kinases, phosphatases, transmembrane receptors, 
and transcription factors [1, 5, 8]. In addition, 14-3-3 has 
been shown to bind to client proteins in a phosphorylation-
independent manner. For example, 14-3-3 can activate the 
Exoenzyme S ADP-ribosyltransferase, a prokaryotic protein 
factor secreted by Pseudomonas aeruginosa [9]. The identi-
fication of high affinity peptides as 14-3-3 binding se-
quences, such as R18, by phage display technology further 
validates this mode of nonphosphorylation-dependent 14-3-3 
interaction [10]. Through these interactions, 14-3-3 proteins 
participate in the regulation of a wide range of vital cellular 
processes, including cell proliferation, cell cycle progression, 
and apoptosis, as well as in a number of pathophysiological 
conditions, such as cancer and neurodegenerative diseases. 
Thus, understanding the mechanisms that govern 14-3-
3/client protein interactions will provide critical insight into 
the control of intracellular signal transduction. Availability 
of 14-3-3 modulators is expected to greatly facilitate our 
mechanistic investigation of 14-3-3 functions. These 14-3-3  
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modulators may become leads for potential therapeutic de-
velopment.  
 
Fig. (1). 14-3-3 binds phosphorylated Ser/Thr motifs with 
RSxpS/TxP as a prototype. It plays an important role in multiple 
signaling pathways.  
 
  In order to identify small molecule 14-3-3 modulators, 
fluorescent polarization (FP) assays have been reported [11, 
12]. The FP-based assays are widely used for high-
throughput screening (HTS) due to their simplicity and sen-
sitivity. However, they are prone to interference by fluores-
cent compounds and are not applicable for protein-protein 
interactions. Here we describe an alternative HTS assay for-
mat for 14-3-3 proteins based on the AlphaScreen (Ampli-
fied Luminescent Proximity Homogenous Assay) technology 
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[13, 14]. AlphaScreen offers a bead-based, non-radioactive 
homogenous assay that can be adapted to small volumes in a 
microplate format. It can be used either as a primary HTS 
assay or as a confirmative assay and has added value by al-
lowing the detection of interactions between two full length 
proteins. Using both phosphorylated and nonphosphorylated 
client targets of 14-3-3 proteins, we have designed and tested 
AlphaScreen-based 14-3-3 assays for HTS. These assays 
have been further optimized and validated with known pep-
tide inhibitors for the screening of small molecule 14-3-3 
inhibitors. 
EXPERIMENTAL PROCEDURES 
Purification of Recombinant 14-3-3 and GST-R18 Pro-
teins 
 Recombinant  14-3-3 protein was expressed in Es-
cherichia coli strain BL21 (DE3) as a glutathione S–
transferase (GST)-tagged or hexaHistidine (His)-tagged 
product as previously described [11]. Similarly, GST-R18 
fusion protein was overexpressed in E. Coli.  E. coli BL21 
(DE3) strains were grown in LB/ampicillin medium for pro-
tein auto-induction. After overnight shaking at 37°C, the 
cells were harvested and the pellets were resuspended in ice-
cold PBS buffer supplemented with phenylmethylsulfonyl 
fluoride (1.0  mM), leupeptin (1μg/ml), and aprotinin 
(1μg/ml). The resuspended pellets were sonicated and 
cleared by centrifugation at 4°C (16,000 g, 15 min). His-
14-3-3 protein was purified by a Ni
2+-charged His-binding 
column (Novagen) as previously described [9], and used for 
biotinylation. GST-14-3-3 and GST-R18 proteins were pu-
rified using a glutathione-conjugated Sepharose column (GE 
Healthcare) [11]. The isolated protein fractions containing 
14-3-3 were desalted using a PD-10 desalting column (GE 
Healthcare) equilibrated in HEPES buffer. The purified pro-
teins were stored at -20ºC before use. 
Basic Assay Development 
  The AlphaScreen binding assay was carried out in 384-
well, white
 Proxiplates (PerkinElmer, Boston, MA) in a total 
volume of 20 l. The AlphaScreen GST detection kit was 
from PerkinElmer Life Science.  
  To test the feasibility of the assay platform, we detected 
the binding of 14-3-3 to R18 peptide. R18 
(PHCVPRDLSWLDLEANMCLP) is an unphosphorylated 
peptide derived from phage display which exhibits a high 
affinity for 14-3-3 proteins [10]. The AlphaScreen donor 
beads were supplied as streptavidin-coated, and the acceptor 
beads were conjugated to an anti-GST antibody. Biotinylated 
14-3-3 protein was generate using EZ-Link
TM  sulfo-NHS-
LC-biotin (Pierce) with purified His-14-3-3, while the GST-
R18 fusion protein was purified from bacterial cells as de-
scribed above. To ensure the integrity of the biotinylated 
His-14-3-3, its binding properties were verified using a pre-
viously developed FP assay [11].  
  Different concentrations of biotin-14-3-3 protein and 
GST-R18 were mixed together in 384-well plates (5 μl/well). 
After a 1 h incubation, acceptor beads (5l/well) were added 
and incubated for 30 min. Donor beads (10 μl/well) were 
subsequently added and incubated for 1.5 h before reading 
with an EnVision multilabel reader (PerkinElmer life Sci-
ence). The final concentration of donor and acceptor beads 
was 20 g/ml. All dilutions were made in HEPES buffer 
(10mM HEPES, 150mM NaCl, 0.05% Tween-20, 0.5 mM 
DTT). Due to the light sensitivity of the donor and acceptor 
beads, the bead dispensing and reading steps were carried 
out under dim light conditions. 
  For the detection of the 14-3-3 protein binding to a Raf-
1-derived phosphopeptide, pS259-Raf-1 [6] , biotintylated-
pS259-Raf- peptide (Biotin-LSQRSTpSTPNVHM) was cus-
tom synthesized (Anaspec, Inc.) and used in an AlphaScreen 
assay with purified GST-14-3-3. The binding experiments 
were conducted similarly as described above for biotin-14-3-
3 protein and GST-R18. 
Peptide Competition Assays 
  In order to verify the specificity of the 14-3-3 binding 
assay, two untagged antagonist peptides of 14-3-3 proteins, 
R18 and a phosphorylated pS967-ASK1- peptide, were used 
to test their ability to displace the GST-R18 or biotin-pS259-
Raf from 14-3-3 proteins. An R18 mutant peptide and a non-
phosphorylated ASK1 peptide were used as controls. Pep-
tides were synthesized at the Emory Microchemistry Facility 
and dissolved in HEPES buffer as stocks. Within each bind-
ing experiment, dose-dependent competition was carried out 
with serial dilutions of peptides, prepared in HEPES buffer. 
In a 384-well plate, 0.5 μl of each diluted untagged peptide 
was added to 4.5 l of the assay mixtures (biotin-14-3-3 
and GST-R18 or GST-14-3-3 and biotin-pS259-Raf). For 
each assay, background (one binding component only) and 
control (without competition peptide) samples were included 
in each assay plate. The competitive effect of the peptides on 
binding was expressed as a percentage of control Alpha sig-
nal as the following:  
% of control =
Alpha signal (control) - Alpha signal (background)
Alpha signal (peptide) - Alpha signal (background)
 100
 
  Data were plotted against log10 value of peptide concen-
trations and analyzed using Prism 4.0 software (Graphpad 
Software, San Diego, CA). IC50 values were determined by 
non-linear curve fitting as the concentrations of the peptides 
at which 50% of control Alpha signal was inhibited. 
High-Throughput Screening Assay Performance 
  To monitor assay sensitivity, signal-to-background (S/B) 
ratios were calculated by the following equation:  
S/B = mean signal binding / mean background 
  To evaluate the quality and suitability of the 14-3-3 bind-
ing assay using AlphaScreen for HTS, we determined the Z’ 
factor [15]: 
Z’ = 1- (3SD of control + 3SD of background) / (mean of 
control – mean of background). 
  To monitor the robustness and reproducibility of the 384-
well HTS format, the means of both background and control 
Alpha signal from each assay plate were obtained and ana-
lyzed by a scatter plot.  
RESULTS AND DISCUSSION 
  AlphaScreen technology provides a proximity-dependent 
homogenous assay format for studying molecular interac-
tions [13, 14]. This assay system contains two beads, a “do-
nor” bead and an “acceptor” bead. Donor beads contain the 42    Current Chemical Genomics, 2008, Volume 2  Du et al. 
photosensitizer phthalocyanine, which upon illumination at 
680 nm converts ambient oxygen to an excited form of oxy-
gen, singlet oxygen. If an acceptor bead is within the energy 
diffusion range (< 200 nm) in solution, energy is transferred 
from the singlet oxygen to thioxene derivatives within the 
acceptor bead, resulting in light production at 520-620 nm 
(Fig. 2). The proximity of these two beads can be induced by 
interaction of two binding components that are coupled to 
the beads. In the AlphaScreen system employed in our study, 
the donor beads were coated with streptavidin and acceptor 
beads were conjugated to anti-GST antibody. Utilizing the 
AlphaScreen technology, we have designed two assay for-
mats for 14-3-3 binding studies. One assay was used for 
monitoring the association of 14-3-3 with the non-
phosphorylated binding peptide R18 (Fig. 2A), while the 
other assay was used for detecting the interaction of 14-3-3 
with a phosphorylated peptide derived from the well-studied 
client protein Raf-1 (Fig. 2B).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (2). Design of AlphaScreen-based 14-3-3 binding assays. (A) 
Biotin-14-3-3 proteins are coupled to streptavidin-coated donor 
beads (D) while GST-R18 is attached to anti-GST antibody-coated 
acceptor beads (A). (B) Biotinylated pS259-Raf-1 peptides are cou-
pled to streptavidin-coated donor beads while GST-14-3-3 proteins 
are attached to acceptor beads with coated anti-GST antibodies. 
Interaction of 14-3-3 with R18 or pS259-Raf-1 leads to generation 
of luminescence signals at the indicated wavelength. 
 
Interaction of 14-3-3 with R18  
  To test the feasibility of using the AlphaScreen technol-
ogy for monitoring the interaction of 14-3-3 with its client 
proteins, we utilized the well-established association of 14-3-
3 with a high affinity peptide, R18, as a model system. Ex-
aminations by mutational and structural approaches have 
conclusively established that R18 docks in the ligand binding 
site of 14-3-3 that is also used by natural client proteins [10, 
16]. Functionally, R18 can effectively compete with other 
natural proteins for the binding of 14-3-3 proteins [17]. 
Thus, the 14-3-3/R18 interaction was utilized to provide a 
proof-of-concept for the development of an HTS assay with 
the AlphaScreen technology platform.  
  The AlphaScreen requires the coupling of test protein 
components onto specific donor and acceptor beads. Accord-
ingly, we generated biotinylated His-14-3-3 protein for cou-
pling to the streptavidin-coated donor beads (Fig. 2). To 
ensure that the biotinylation did not compromise the bind-
ing activity of 14-3-3 proteins, we examined the interaction 
of the biotin-14-3-3 protein with a Raf-1 peptide using a FP 
assay [11]. Biotinylation appeared to have no obvious effect 
on the binding properties of 14-3-3, with a KD (0.76 μM) 
comparable to nonbiotinylated 14-3-3 (KD of 0.42 μM [11]; 
Fig. 3A). For generating the corresponding acceptor beads, a 
GST-tagged R18 protein-peptide fusion was purified for 
coupling to the anti-GST antibody-coated beads. We used 
the R18 fusion protein in order to place the 14-3-3 recogni-
tion sequence within the context of a full length protein to 
mimic the situation in natural 14-3-3 client proteins. Our 
previous studies demonstrated that the fusion of GST had no 
detectable effect on the efficacy of R18 for 14-3-3 binding 
[10]. These reagents were then added to the reaction in dif-
ferent sequences or combinations before the Alpha lumines-
cence signal was recorded. As shown in Fig. (3B), when 
biotin-14-3-3 proteins (5 nM, 10 nM, or 30 nM) were incu-
bated with the donor and acceptor beads in the absence of 
GST-R18, only a low background Alpha signal (~2,000 
counts) was generated. However, the addition of increasing 
concentrations of GST-R18 (5 nM to 500 nM) to the biotin-
14-3-3 solutions (5 nM or 10 nM) induced the robust pro-
duction of Alpha signal in a dose-dependent manner. The 
specific Alpha signal, calculated by subtracting the back-
ground counts, approached approximately 46,000 counts 
with 5 nM of biotin-14-3-3 and 10 nM of GST-R18. The 
S/B ratio of the assay reached beyond 10 under the condi-
tions tested, which defines an excellent assay window (Fig. 
3C). Further increases in the GST-R18 concentration beyond 
100 nM or the biotin-14-3-3 protein concentration beyond 30 
nM resulted in a decrease in Alpha signal and S/B ratio. This 
“hooking effect”, an effect common to many immunoassays 
relying on antibody recognition and binding of target mole-
cules, is likely due to the saturation of available binding sites 
on one or both of the AlphaScreen beads [18]. It has been 
shown that Alpha signal increases with increasing target 
molecule concentrations up to a point, after which the target 
molecules will become inhibitory to the production of Alpha 
signals [19, 20]. These studies suggest that the AlphaScreen 
assay platform can be used to monitor the interaction of 14-
3-3 with its binding partners.  
  To evaluate the quality and suitability of the AlphaScreen 
assay for HTS in a 384-well microplate format, the Z’ fac-
tors were determined. The Z’ factor incorporates the dy-
namic assay range and the assay variability into a single met-
ric, and is a parameter for the quality of the assay itself with-
out test compounds [21]. The Z’-factor is widely utilized for 
quality assessment in assay development and optimization. 
Assays with Z’ factors between 0.5 and 1 (the maximum) are 
considered of high quality and suitable for automation and 
the subsequent screening. As shown in Fig. (3D), when bio-
tin-14-3-3 at a concentration of 5 nM or 10 nM was incu-
bated with GST-R18 (5 nM, 10 nM, or 30 nM), the calcu-
lated Z’ values were all above 0.7, supporting a robust assay 
format. Thus, this AlphaScreen assay for the 14-3-3 and R18 
interaction can be further developed for HTS of 14-3-3 
modulators.  
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Fig. (3). AlphaScreen assay for measuring the interaction of 14-3-3 with R18. (A) Biotinylation has no effect on the ligand binding capabil-
ity of His-14-3-3 proteins. Binding of biotin-14-3-3 to pS259-Raf-1 peptide was determined by FP assay [11]. Biotin-14-3-3 proteins were 
incubated with a TMR-pS259-Raf peptide (1 nM) at RT for 30 min and the FP signal [expressed in millipolarization units (mP)] was read 
with an Analyst HT reader (Molecular Devices). Specific binding (mP) was obtained by subtracting free peptide tracer values from values 
recorded in the presence of 14-3-3 proteins. (B) Interaction of biotin-14-3-3 with GST-R18 generates an Alpha luminescence signal. Increas-
ing concentrations of GST-R18 protein were incubated with biotin-14-3-3 protein at RT for 30 min. Donor and acceptor beads were added 
with an interval of 30 min. The plate was assayed using an EnVision multilabel plate reader after 1.5 hr incubation at room temperature. Data 
are expressed as mean + SD from triplicate samples. (C) S/B ratios of the 14-3-3/R18 AlphaScreen assay. (D) Z’ values of the assay.  
 
 
 
 
 
 
 
 
 
 
Fig. (4). Competition with untagged peptide antagonists, R18 and pS967-ASK1, in the 14-3-3/R18 AlphaScreen assay. Biotin-14-3-3 (5 
nM) and GST-R18 (15 nM) were incubated with increasing concentrations of untagged antagonists at RT for 1 hr. After incubation for 1.5 hr 
upon addition of donor and acceptor beads, Alpha signals were recorded. (A) Competition with the R18 peptide or the mutated control 
(R18Lys) peptide. (B) Competition with pS967-ASK1 or the non-phosphorylated control (ASK1) peptide. The y-axis of the graph represents 
the percentage of the control. The control is defined by maximal Alpha signal obtained in the absence of any inhibitor with background 
counts subtracted. Data are expressed as means + SD from triplicate determinations. 
  To validate the AlphaScreen assay for the discovery of 
14-3-3 inhibitors, we tested inhibition of the interaction of 
14-3-3 with the R18 by two untagged antagonist peptides: an 
R18 peptide and an ASK1 peptide, pS967-ASK1. The 
untagged R18 and pS967-ASK1 peptides are expected to 
compete with GST-R18 for the binding of 14-3-3 proteins. 
Indeed, incubation of increasing concentrations of untagged 
R18 peptide with biotin-14-3-3 and GST-R18 led to a 
dose-dependent decrease in Alpha signal with an IC50 value 
of 28 ± 1.1 nM (Fig. 4A). On the other hand, untagged 
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R18Lys, a R18 peptide with a mutated 14-3-3 binding resi-
due, failed to displace GST-R18 from the 14-3-3 protein, 
supporting a specific effect of the R18 competitor. Many 14-
3-3 client proteins, including ASK1, require phosphorylation 
to mediate the binding to 14-3-3 proteins. The pS967-ASK1 
peptide is a 14-3-3 binding peptide that contains phosphory-
lated Ser-967 and its surrounding sequence within the ASK1 
protein [21, 22]. As shown in Fig. (4B), the free pS967-
ASK1 peptide competed with the binding of GST-R18 to 
14-3-3, resulting in a dose-dependent decrease in Alpha 
signal with an IC50 value of 549.4 ± 1.1 nM. The same 
ASK1 peptide without phosphorylation, however, had no 
effect on the Alpha signal generated from the 14-3-3 binding 
to R18 (Fig. 4B). These results are consistent with reported 
interactions of 14-3-3 with phosphorylated client peptides [6, 
7]. Thus, small molecules that compete for the binding of 
R18 to 14-3-3 proteins can be revealed in the AlphaScreen-
based assay platform.  
Interaction of 14-3-3 with a Raf-1 Peptide 
  With the establishment of a general platform for monitor-
ing 14-3-3 interactions, we extended our study to examine 
the utility of the AlphaScreen technology for the binding of 
14-3-3 to a phosphorylated peptide derived from Raf-1, a 
mitogen-activated protein kinase regulator. It has been well-
established that phosphorylation of Raf-1 at Ser-259 induces 
its association with the 14-3-3 proteins, which plays a critical 
role in Raf-1-mediated cell signaling [6, 8, 23-25]. To test 
the 14-3-3/Raf-1 interaction in the AlphaScreen system, we 
generated a biotinylated Raf peptide, pS259-Raf-1, for cou-
pling to streptavadin-coated donor beads. 14-3-3 was pro-
duced and purified as a GST-tagged fusion protein for cou-
pling to the GST-antibody coated acceptor beads. The 
interaction of biotin-pS259-Raf-1 peptide with GST-14-3-3 
would bring donor and acceptor beads together and induce 
the production of Alpha signal (Fig. 2B). Indeed, mixing 
increasing concentrations of GST-14-3-3 and biotin-pS259-
Raf-1 with both beads resulted in a dose-dependent increase 
in Alpha signal (Fig. 5A). When incubated with 30 or 100 
nM of biotin-pS259-Raf-1, the S/B ratio significantly in-
creased with increasing concentration of 14-3-3 proteins 
(Fig. 5B). The calculated Z’ factors were above 0.6 when 
100 nM of biotin-pS259-Raf-1 was incubated with increas-
ing concentrations of GST-14-3-3 protein (Fig. 5C). Z’ fac-
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (5). AlphaScreen assay for measuring the interaction of 14-3-3 with pS259-Raf-1. Experiments were performed as described in the 
legend to Fig. (4) using 100 nM of GST-14-3-3 and 100 nM of biotin-pS259-Raf-1 peptide. For (A), (D), and (E), data are expressed as 
means + SD from triplicate determinations. (A) Increasing concentrations of GST-14-3-3 protein were incubated with biotin-pS-259-Raf 
peptide at RT for 30 min. Donor and acceptor beads were added with an interval of 30 min. Results were recorded after 3 hr of incubation at 
RT. (B) The S/B ratios of the assay. (C) The Z’ factor of the assay. (D) Competition with the R18 peptide or its mutant peptide, R18Lys, in 
the 14-3-3/pS259-Raf-1 AlphaScreen assay. (E) Competition assay using the pS967-ASK1 or its non-phosphorylated ASK1 control peptide. HTS Assay for 14-3-3 Proteins  Current Chemical Genomics, 2008, Volume 2    45 
tors reached 0.9 when 30 or 100 nM of 14-3-3 was used, 
indicating a robust assay performance.  
  To validate this assay for the screening of 14-3-3 inhibi-
tors, two untagged 14-3-3 peptide antagonists were tested for 
inhibition of the interaction of 14-3-3 with Raf-1. R18 or 
pS967-ASK1 antagonist peptides were incubated with GST-
14-3-3 (100 nM) and biotin-pS259-Raf-1 peptide (100 nM), 
and Alpha signals were recorded. These two 14-3-3 antago-
nists effectively competed with the 14-3-3/Raf-1 binding as 
shown by decreased Alpha signal with the increasing con-
centrations of R18 or pS967-ASK1 peptide (Figs. 5D and 
4E). Importantly, the R18Lys or non-phosphorylated ASK1 
control peptides showed no effect in this assay. The calcu-
lated IC50 values for the R18 peptide was 35.7 ± 1.1 nM and 
for the pS967-ASK1 peptide was 534.9 ± 1.1 nM, which is 
consistent with the results obtained in the 14-3-3/R18 inter-
action assay (Fig. 4). 
HTS Assay Validation 
  One potential use of a homogeneous assay for 14-3-3 
binding is to carry out HTS of chemical libraries for the 
identification of small molecule 14-3-3 inhibitors. In order to 
evaluate the suitability of the AlphaScreen-based 14-3-3 
assays for HTS, a series of experiments were performed. 
  First, the dimethyl sulfoxide (DMSO) tolerance level of 
the assay was evaluated. DMSO is a common solvent used in 
dissolving chemical compounds. To determine the effect of 
DMSO on the AlphaScreen based 14-3-3 assay, experiments 
were performed in the presence of varying amounts of 
DMSO. As shown in Fig. (6A), the Alpha signals for the 
binding of biotin-14-3-3 (5 nM) to GST-R18 (15 nM) were 
not significantly altered in the presence of up to 5% DMSO. 
Then, we determined the assay stability by performing com-
petition experiments and recording the AlphaScreen lumi-
nescence signal over time. As shown in Fig. (6B), the addi-
tion of untagged R18 peptide to the reaction containing bio-
tin-14-3-3, GST-R18, and the donor/acceptor beads, de-
creased the Alpha luminescence signals in a dose-dependent 
manner. No significant difference was noticed when the result 
was recorded either at 1.5 hr or 16 hr after mixing the reac-
tion components. Similar IC50 values were obtained with 
these two time points (28.0 ± 1.1 nM for 1.5 hr and 33.6 ± 
1.1 nM for 16 hr). These results suggest that the AlphaS-
creen assay for HTS of 14-3-3 inhibitors is stable over a time 
period of at least 16 hr, which allows the reading of more 
than 120 microplates (384-well) with the Envision plate 
reader. Finally, we evaluated parameters for HTS perform-
ance and assay consistency by testing well-to-well and plate-
to-plate variation of the binding assay in a total volume of 20 
μl. Each reaction contained 5 nM of biotin-14-3-3 and 15 
nM of GST-R18 as in Fig. (3). The Z’ factor and S/B ratio of 
reactions from ten individual plates were recorded and com-
pared (Figs.7A and 7B). Among these 10 plates, the average 
value for Z’ was 0.73 with a standard deviation of 0.06 and 
the average S/B ratio was 10.6 with a standard deviation of 
2.4, indicating the robustness and suitability of this assay for 
automation. We further evaluated the assay consistency by 
performing the R18 peptide competition assay with the bio-
tin-14-3-3/GST-R18 interaction pair on different days. As 
shown in Fig. (7C), the dose-response curves obtained from 
measurements in two different plates at two different days 
gave rise to similar IC50 values ( 27.3 nM and 43.2 nM, re-
spectively), demonstrating high consistency of the AlphaS-
creen assays.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (6). Evaluation of the DMSO tolerance and stability of the 14-
3-3 AlphaScreen assay. (A) Effect of DMSO on Alpha signal. The 
biotin-14-3-3 (5 nM) and GST-R18 (15 nM) were incubated with 
increasing amounts of DMSO, and reactions were carried out as 
described in the legend to Fig. (4). Results were recorded after in-
cubation with donor and acceptor beads for 1.5 hr. (B) Stability of 
the 14-3-3 AlphaScreen assay as evaluated in R18 competition 
assay. Experiments were carried out as described in Fig. (4) except 
that results were recorded after incubation for 1.5 hr or 16 hr. Dose-
response data with the untagged R18 peptide antagonist were ex-
pressed as the percentage of maximal Alpha signal control that was 
obtained from samples in the absence of inhibitor. Data are ex-
pressed as means + SD from triplicate determinations.  
CONCLUSIONS 
  We have developed and optimized a HTS assay in a 384-
well format by using the AlphaScreen technology for the 
detection of 14-3-3 protein interaction with both phosphory-
lated and nonphosphorylated client peptides. Experimental 
conditions for both 14-3-3/R18 and 14-3-3/pS259-Raf-1 
pairs have been established that gave rise to a robust assay 
performance with S/B ratio above 7 and Z’ factors above 0.7. 
Further validation experiments provided evidence that the 
competitive 14-3-3 binding assays using AlphaScreen can be 
used for HTS for the screening of 14-3-3/client peptide in-
teraction inhibitors. These assays utilize a small amount of 
test proteins (low nM) in a low volume (20 μl), which makes 
them particularly suited for HTS. It is expected that this as-
say is also applicable for monitoring the interaction of 14-3-
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3 with its full length client proteins in future HTS cam-
paigns. 
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Fig. (7). Evaluation of the 14-3-3 AlphaScreening assay for HTS. 
The binding assay was performed essentially as described in Fig. 
(4), using biotin-14-3-3 (5 nM) and GST-R18 (15 nM) and 10 
assay plates (384-well). (A) Z’ factor for the 14-3-3 AlphaScreen 
assay. The Z’ values across the 10 plates were consistently higher 
than 0.7. (B) The S/B values, calculated for each of the 10 plates, 
were all above 7. (C) Day to day variation. Day to day precision 
was assessed by comparison of 2 representative dose-response 
competition curves of R18 peptide which were performed on 2 
different days. Results are shown as a percentage of control Alpha 
signal (obtained in the absence of inhibitor) after subtracting the 
background (biotin-14-3-3 only). Data are expressed as means + 
SD from triplicate determinations. 
C
1 10 100 1000 10000
0
20
40
60
80
100
Day1
IC50=27.3 nM
R18 peptide (nM)
%
 
o
f
 
C
o
n
t
r
o
l
A
Plate Number
Z
’
B
Plate Number
S
/
B
Day2
IC50= 43.2 nMHTS Assay for 14-3-3 Proteins  Current Chemical Genomics, 2008, Volume 2    47 
[22]  Subramanian RR, Zhang H, Wang H, Ichijo H, Miyashita T, Fu H. 
Interaction of apoptosis signal-regulating kinase 1 with isoforms of 
14-3-3 proteins. Exp Cell Res 2004; 294(2): 581-91. 
[23]  Fantl WJ, Muslin AJ, Kikuchi A, et al. Activation of Raf-1 by 14-
3-3 proteins. Nature 1994; 371(6498): 612-4. 
[24]  Freed E, McCormick F, Ruggieri R. Proteins of the 14-3-3 family 
associate with Raf and contribute to its activation. Cold Spring 
Harb Symp Quant Biol 1994; 59: 187-93. 
[25]  Fu H, Xia K, Pallas DC, et al. Interaction of the protein kinase Raf-
1 with 14-3-3 proteins. Science 1994; 266(5182): 126-9. 
 
 
 
Received: July 30, 2008  Revised: September 01, 2008  Accepted: September 02, 2008 
 
© Du et al.; Licensee Bentham Open. 
 
This is an open access article licensed under the terms of the Creative Commons Attribution Non-Commercial License 
(http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted, non-commercial use, distribution and reproduction in any medium, provided the 
work is properly cited. 